At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 663 enrolled
Drug / intervention
omega-3-acid ethyl esters +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation
In Brief
A Phase 3 clinical trial evaluating omega-3-acid ethyl esters and Placebo for Fibrillation, Atrial. Completed, enrolled 663 participants across 178 sites.
Detailed Summary
The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibrillation, Atrial
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedNov 2006
Primary CompletionJan 2010
TodayJul 2026
First PostedNov 22, 2006
Enrollment StartNov 1, 2006
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 19.6 years ago
Interventions
omega-3-acid ethyl estersdrug
Placebodrug